Laura Prendergast analyst STIFEL

Currently out of the existing stock ratings of Laura Prendergast, 39 are a BUY (95.12%), 2 are a HOLD (4.88%).

Laura Prendergast

Work Performance Price Targets & Ratings Chart

Analyst Laura Prendergast, currently employed at STIFEL, has had 31.49% of price targets met with an average potential upside of 23.2%, reached in 49 days on average. Previously, Laura Prendergast worked at RAYMOND JAMES.

Laura Prendergast has documented 81 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on OLMA, Olema Pharmaceuticals at 14-Sep-2026.

Wall Street Analyst Laura Prendergast

Analyst best performing recommendations are on ERAS (ERASCA).
The best stock recommendation documented was for ERAS (ERASCA) on 1/12/2026. The price target of $10 was fulfilled within 9 days with a profit of $3.77 (60.51%), with a performance score of 67.24.

Average potential price target upside

BDTX Black Diamond Therapeutics COGT Cogent Biosciences ERAS Erasca MURA Mural Oncology plc NUVL Nuvalent RVMD Revolution Medicines TNGX Tango Therapeutics NKTX Nkarta OLMA Olema Pharmaceuticals FHTX Foghorn Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 22-Nov-2023

$11

$9.53 (648.30%)

$11

20 days ago
(29-Oct-2026)

0/14 (0%)

$9.14 (491.40%)

Buy Since 30-Sep-2025

$7

$5.53 (376.19%)

$6

7 months 26 days ago
(23-Mar-2026)

0/2 (0%)

$4.85 (225.58%)

Buy Since 12-Sep-2023

$14

$12.53 (852.38%)

$16

8 months 1 days ago
(17-Mar-2026)

0/11 (0%)

$11.77 (527.80%)

Buy Since 18-Nov-2025

$8

$6.53 (444.22%)

$9

10 months 2 days ago
(16-Jan-2026)

0/2 (0%)

$5.44 (212.50%)

Buy Since 14-Dec-2023

11 months 14 days ago
(04-Dec-2025)

1/6 (16.67%)

$5.12 (177.78%)

83

Show more analysts

Please expand the browser size to see the chart

Which stock is Laura Prendergast most bullish on?

Potential upside of $67.31 has been obtained for RVMD (REVOLUTION MEDICINES)

Which stock is Laura Prendergast most reserved on?

Potential downside of $11.04 has been obtained for NUVL (NUVALENT)

What Year was the first public recommendation made by Laura Prendergast?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?